SteadyMed Announces FDA Agreed Pathway to Trevyent NDA Resubmission Post author:Sam Post published:December 7, 2017 Post category:BioPharma No clinical trials are required for the NDA resubmission. Source: BioSpace You Might Also Like Greiner Bio-One Inc. Launches New Innovative CELLdisc Product For Mass Cell Culture February 9, 2017 Auris Med Announces Receipt Of Nasdaq Notice August 24, 2017 SoCal's Vical Terminates 54% of Workforce to Focus Resources on Two Clinical Programs January 30, 2018
SoCal's Vical Terminates 54% of Workforce to Focus Resources on Two Clinical Programs January 30, 2018
